The research team of the AstraZeneca pharmaceutical group announces amazing progress in developing a potential vaccine against the new type of virus. Only things got stuck for the moment, and the tests were suspended when it was thought that everything was going well.
Researchers around the world are working on automatic fire to develop a vaccine against the new type of virus. Progress is being made in America, China, but in Europe. The most promising news came from the pharmaceutical group AstraZeneca, which had already gone through several test phases.
However, the trial has now been suspended due to the fact that one of the volunteers suffered, according to the specialists, from an inexplicable illness.
Clinical trials were suspended after teams of researchers from AstraZeneca and Oxford University reported an unexplained disease in a study participant. AstraZeneca described the shutdown as a “routine break”, with the procedure likely to resume in a few days.
Even if it is considered that there is nothing serious or that the process can be improved, the suspension of the tests overturns the schedule assumed by AstraZeneca and those from Oxford, who promised that there are chances to put the product on the market. âºUntil the end of the year. So far, the company has not given details about the nature of the volunteer's illness nor about his condition. However, he stated that he will be healed.
However, it is also up to the regulators to decide whether the tests will be resumed or not.
“In large studies, such random illnesses will always occur, but they must be checked independently before proceeding,” said a spokesman for Oxford University.
Testing of the AstraZeneca vaccine, called AZD1222, is taking place at various stages in the United Kingdom, the United States, Brazil, South Africa and India, and the number of volunteers is about 30,000.
It should be noted that the EU has great confidence in the development of this vaccine and has decided to purchase 300 million doses in advance. The British-Swedish pharmaceutical group has received confirmation that the first 300 million doses of vaccine will be bought by the European Commission itself. Of these, Romania would have to recover somewhere over one million.